Becton, Dickinson and Company Earnings Call Transcripts
Fiscal Year 2026
-
Aggressive hedging and diversified sourcing insulate from oil and supply shocks, while strategic divestitures and tuck-in M&A have built new growth platforms. Alaris relaunch and connected care innovations drive competitive gains, with high-growth areas and AI integration supporting a positive outlook.
-
Q1 results exceeded expectations with $5.3B revenue and strong growth in key platforms. The Life Sciences business was divested to Waters, unlocking $4B for share repurchases and debt paydown. Fiscal 2026 guidance calls for steady low single-digit revenue growth and 6% EPS growth at midpoint.
-
Record revenue and margin growth were reported, with strong shareholder returns and the 54th consecutive dividend increase. All board and compensation proposals passed by wide margins, and a major business combination was announced to drive future growth.
Fiscal Year 2025
-
Q4 and FY2025 delivered record revenue and EPS growth, with strong margin expansion and robust cash flow. FY2026 guidance reflects macro headwinds but expects continued mid-single digit growth for most of the portfolio, supported by innovation and capital returns.
-
Management outlined four key priorities: completing the Waters separation, driving commercial and margin expansion strategies, and focused capital allocation with a bias toward share buybacks. Growth is supported by innovation in biologics, AI, and interventional products, with prudent guidance for FY 2026 amid macro uncertainty.
-
Q3 saw 8.5% revenue growth to $5.5B, margin expansion, and strong innovation launches. Guidance for FY2025 was raised, with organic growth expected to improve and a major business separation with Waters Corporation progressing. Tariff impacts are being actively mitigated.
-
Waters will combine with BD's Biosciences and Diagnostic Solutions via a $17.5B reverse Morris trust, creating a leader in regulated life science and diagnostics with a $40B addressable market. The deal brings significant cost and revenue synergies, targets 32% margins by 2030, and is expected to close by Q1 2026.
-
Separation of biosciences/life sciences is progressing, with sale or merger prioritized for value. Despite macro headwinds from China, research funding, and pharma destocking, innovation and operational excellence are driving margin expansion and future growth, with a robust pipeline and share buybacks prioritized.
-
Management outlined recent headwinds from China, NIH funding, and BACTEC recovery, leading to reduced guidance and a focus on commercial excellence and innovation. Margin expansion is driven by operational initiatives, while the life sciences separation remains on track for a summer announcement.
-
Q2 organic revenue growth slowed to 0.9% due to Life Sciences and China headwinds, but strong margin expansion and cost controls drove adjusted EPS up 5.7%. Full-year organic growth guidance was lowered to 3%-3.5%, with ongoing tariff mitigation and new product launches expected to accelerate growth in the second half.
-
A growth-focused MedTech strategy is driving strong segment performance, with a planned separation of the life sciences business to unlock further value. Investments in AI, connected care, and high-growth platforms are accelerating innovation, while margin improvements are fueling reinvestment in R&D and targeted M&A.
-
Management detailed plans to separate the Biosciences division, focusing on a high-growth, MedTech-centric NewCo with strong recurring revenue and innovation in biologics, interventional, and connected care. Q1 results exceeded expectations, and new launches like Pyxis Pro and BD Connected are set to drive future growth.
-
Q1 fiscal 2025 saw strong revenue and EPS growth, significant margin expansion, and robust cash flow. The company announced plans to separate its Biosciences and Diagnostic Solutions business, aiming to unlock value and enhance strategic focus for both entities.
Fiscal Year 2024
-
Strong 2024 growth was achieved despite market headwinds, with 2025 guidance reflecting continued caution in China and select segments. Margin expansion, robust cash flow, and targeted share buybacks support nearly 10% earnings growth. Innovation and product launches in interventional and Pharm Systems drive future upside.
-
Delivered strong Q4 and FY24 results with robust margin expansion, EPS growth, and free cash flow. FY25 guidance anticipates high single-digit revenue growth, continued margin improvement, and disciplined capital allocation, despite headwinds in China and bioscience pharma.
-
Management outlined a focus on innovation, operational excellence, and portfolio optimization, with strong momentum in automation, AI, and core franchises like Alaris and PureWick. Margin and EPS growth are expected to continue, supported by efficiency programs and new product launches.
-
Q3 delivered 5.2% organic revenue growth, strong margin expansion, and 18% EPS growth, with robust performance in Alaris, PureWick, and biologics. FY 2024 guidance was raised, and FY 2025 is expected to deliver double-digit EPS growth and margin improvement, despite ongoing headwinds in China and Biosciences.